# Idelalisib Post Allogeneic Hematopoietic Stem Cell Transplant (HSCT) in B Cell Derived Malignancies

> **NCT03151057** · PHASE1 · TERMINATED · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins** · enrollment: 16 (actual)

## Conditions studied

- B Cells-Tumors
- B Cell Chronic Lymphocytic Leukemia
- Follicular Lymphoma
- Mantle Cell Lymphoma
- Large B-Cell Diffuse Lymphoma of Bone (Diagnosis)

## Interventions

- **DRUG:** Idelalisib 100 MG
- **DRUG:** Placebo Oral Tablet

## Key facts

- **NCT ID:** NCT03151057
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-07-31
- **Primary completion:** 2022-06-20
- **Final completion:** 2022-07-20
- **Target enrollment:** 16 (ACTUAL)
- **Why stopped:** Safety endpointreached
- **Last updated:** 2024-03-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03151057

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03151057, "Idelalisib Post Allogeneic Hematopoietic Stem Cell Transplant (HSCT) in B Cell Derived Malignancies". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03151057. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*